Literature DB >> 30206805

Adipose insulin resistance is associated with cardiovascular risk factors in polycystic ovary syndrome.

L Mu1,2,3,4, R Li1,2,3, Y Lai1,5, Y Zhao6,7,8, J Qiao1,2,3,4,5.   

Abstract

PURPOSE: The effects of adipose insulin resistance on cardiovascular risk factors in polycystic ovary syndrome (PCOS) remain largely unknown. We aimed to investigate associations between adipose insulin resistance and cardiovascular risk factors in PCOS.
METHODS: A total of 207 PCOS and 47 non-PCOS women were recruited from a large reproductive medicine center in this cross-sectional study. The PCOS diagnosis was based on the Rotterdam Criteria. The subjects received a standard oral glucose tolerance test. Adipose insulin resistance was evaluated using a validated index (adipose-IR = fasting insulin × free fatty acid concentrations).
RESULTS: The women with PCOS showed a higher adipose-IR index, and the adipose-IR index was tightly associated with the blood pressure, glucose and lipid parameters. A total of 98.0% of the women with PCOS in the highest adipose-IR quartile showed cardiovascular risk factors (obesity, hypertension, glucose intolerance or dyslipidemia), and this percentage was significantly higher than the percentage of those in the lowest quartile (32.7%). In addition, the percentages of women with three (31.4%) and four (13.7%) cardiovascular risk factors were significantly elevated in the highest adipose-IR quartile. The multivariable logistic regression analysis indicated that each 1-SD increment in the adipose-IR index resulted in higher risks of obesity (OR = 3.18, 95% CI = 2.12-4.76), hypertension (OR = 1.89, 95% CI = 1.31-2.73), glucose intolerance (OR = 2.45, 95% CI = 1.73-3.48), and dyslipidemia (OR = 2.18, 95% CI = 1.57-3.01). The C-reactive protein (CRP) level was positively associated with the adipose-IR index in women with PCOS (r = 0.45, P < 0.001).
CONCLUSIONS: The adipose-IR index was associated with cardiovascular risk factors in women with PCOS. Chronic inflammation may induce insulin resistance in the adipose tissue of women with PCOS.

Entities:  

Keywords:  Adipose tissue; Insulin resistance; Metabolic syndrome; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2018        PMID: 30206805     DOI: 10.1007/s40618-018-0949-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  6 in total

1.  Relationship between surrogate estimates and direct measurement of insulin resistance in women with polycystic ovary syndrome.

Authors:  M H Dahan; F Abbasi; G Reaven
Journal:  J Endocrinol Invest       Date:  2019-01-30       Impact factor: 4.256

2.  Unique Metabolic Features of Adults Discordant for Indices of Insulin Resistance.

Authors:  Yilin Song; Esben Søndergaard; Michael D Jensen
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

3.  Association between neutrophil-to-lymphocyte ratio and polycystic ovary syndrome: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Li Li; Jianxiu Yu; Zhongwei Zhou
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

4.  Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).

Authors:  A Podfigurna; B Meczekalski; F Petraglia; S Luisi
Journal:  J Endocrinol Invest       Date:  2019-10-25       Impact factor: 5.467

Review 5.  Coordinated Modulation of Energy Metabolism and Inflammation by Branched-Chain Amino Acids and Fatty Acids.

Authors:  Zhenhong Ye; Siyu Wang; Chunmei Zhang; Yue Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-08       Impact factor: 5.555

6.  Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome.

Authors:  P Falcetta; E Benelli; A Molinaro; C Di Cosmo; B Bagattini; S Del Ghianda; G Salvetti; E Fiore; E Pucci; F Fruzzetti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2021-06-05       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.